
14 Million People Could Die in Next 5 Years Due to USAID Cuts, Study Finds
An international group of researchers conducted the study, published Monday in the Lancet. They estimated that USAID funding in developing countries has helped save dozens of millions of lives since 2001, while the drastic cuts dictated by Musk and his Department of Government Efficiency (DOGE) could contribute to 14 million deaths in the next five years, including many children under 5 years old.
'Our estimates show that, unless the abrupt funding cuts announced and implemented in the first half of 2025 are reversed, a staggering number of avoidable deaths could occur by 2030,' the researchers wrote.
The renewed Trump administration has gutted many crucial government agencies and departments since January, including the Centers for Disease Control and Prevention. But perhaps none of the cuts have been as vicious as those to the USAID, the agency primarily in charge of distributing the country's foreign aid.
Though the USAID certainly has its blemishes (government watchdogs have alleged that its funding contributed to widespread fraud during America's occupation of Afghanistan, for instance), it's been a net positive for global public health. USAID resources have bolstered programs throughout the world to provide people vaccines, anti-malaria mosquito nets, and other vital medical supplies. One particular USAID-operated initiative, the President's Emergency Plan for AIDS Relief (PEPFAR), is estimated to have prevented over 5 million children from being born with HIV.
Unelected Billionaire Elon Musk Is Shutting Down the Government Agency USAID
Musk and others within the Trump White House seemed to take a perverse joy in sabotaging the USAID through widescale cuts and layoffs. In early February, Musk bragged on X that he had 'spent the weekend feeding USAID into the wood chipper.' While USAID employees have challenged these layoffs in court, arguing they were illegal and unconstitutional, the agency remains critically underfunded and shorthanded.
The study researchers first looked back at the life-saving impact that USAID funding has had globally, then projected how the current loss of resources will change things moving forward. Based on data from over 130 countries, they estimated that USAID funding had likely saved 91 million lives between 2001 and 2021, with the largest reductions in mortality tied to HIV/AIDS, malaria, and neglected tropical diseases. They also forecasted that the DOGE-mandated cuts will result in 14 million preventable deaths by 2030, including 4.5 million deaths of children under 5.
'Our analysis shows that USAID funding has been an essential force in saving lives and improving health outcomes in some of the world's most vulnerable regions over the past two decades,' said lead author Daniella Cavalcanti, a postdoctoral researcher at the Federal University of Bahia's Institute of Collective Health in Brazil, in a statement. Scientists from the Barcelona Institute for Global Health in Spain and the University of California, Los Angeles, also contributed to the study.
Trump's 'Big Beautiful Bill' Will Literally Kill, Study Warns
Musk is no longer officially part of President Donald Trump's inner circle, his designation as a special government employee having run out in late May. And after a brief ceasefire, he and Trump have continued to throw barbs at each other over the GOP's Big Beautiful Bill (which itself may lead to many preventable deaths from Medicaid cuts). But DOGE and many of the cuts it's implemented continue to endure. Other recent reports from aid groups indicate that people are already dying as a result of these funding losses.
Unless things change dramatically, Musk's legacy will be one stained with the blood of the poor and vulnerable.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
34 minutes ago
- Fast Company
How China is leading the humanoid robots race
I've worked at the bleeding edge of robotics innovation in the United States for almost my entire professional life. Never before have I seen another country advance so quickly. In the span of the last few years, China has overtaken the U.S. as the leader in the robotics race, especially when it comes to humanoid robots designed to mimic the human body and behavior. Earlier this year China literally raced robots against human counterparts, and they show no sign of slowing down. While AI steals the investment and media spotlight, the competition for humanoid robotics supremacy has been quietly accelerating for 50 years, and we're now on the cusp of a momentous breakthrough. Mass-produced humanoid robots may reach us within the next 3–5 years, and the market is predicted to grow to $38B within just 10 years. China is poised to capture the lion's share of this industry: Morgan Stanley found that 56% of robotics companies are already based there. However, this competition isn't just about market share—it's about industrial supremacy. Fixed industrial robots now operate with productivity rates estimated to be 10 times that of humans, working almost 24/7 with virtually no errors. In this new era of free-moving humanoid robots, adaptable machines will navigate entire factory floors with equal precision and even higher productivity rates than their fixed (and human) counterparts. American companies like Boston Dynamics are building impressive prototypes but those don't win industrial wars, production does. If the U.S. continues to lag behind in the robotics race, American businesses will face increased supply chain dependence on China and citizens could see wage stagnation and job losses to robotics leaders overseas. I witnessed the U.S. lead the world in robotic advancements. Two of my humanoid robots went into space; one called 'Robonaut' now lives in the Smithsonian. Over the past decade, our momentum has slowed. To take back robotics supremacy, the U.S. must overcome four critical hurdles that could cost us this race. Why the U.S. Isn't 'All-In' on Humanoids Yes, Chinese robotics startups are benefiting from established supply chains, local adoption opportunities, and strong national government support, but nagging domestic problems are holding the United States back, regardless of any other country's advancements. First, we're battling our own cultural fears. There's a prevailing anxiety that robots will replace human jobs, particularly in factories. While massive change in manufacturing is fast approaching, the fear of replacement is not only wrong—it's counterproductive. Humanoid robots excel at 'dirty, dark, and dangerous' jobs that often lack willing human labor anyway. To overcome U.S. cultural fears around robotics, we must think of robots not as standing in our place but standing by our sides. WWII was won as much on the mechanized manufacturing floor as on the battlefield and novel machines were essential to winning the space race. When Robonaut shook hands with a fellow astronaut aboard the International Space Station, it was proof that robots can and should support human work, not compete with it. Second, we're not cultivating the people behind the humanoids. The real challenge in winning the humanoid race isn't job displacement; it's the massive lack of skilled domestic workers to develop, operate, and maintain advanced robotics. At Texas A&M, I teach brilliant students ready to tackle real-world problems with robots. Educating the workforce about how to leverage robots will empower the next generation and dispel fear. However, across the country, preparation for careers in STEM is lacking. We need more accessible science programs, apprenticeships, and pathways into robotics now. Third, the economics still intimidate us. Developing humanoid robots involves significant upfront costs and still faces expensive technical hurdles, including improving spatial awareness and task adaptability. But here's what the bean counters are missing: once mass production kicks in, the cost of robot labor could plummet from $10 to just $0.25 per hour in as little as 10 years. The industry will transform overnight and whichever country controls this shift owns the future of manufacturing. Focusing on the future affordability of robot labor will incentivize both the private and public sector to invest now. Fourth, our policy framework is falling behind. While the U.S. offers some incentives for research and innovation, they pale in comparison to China's commitment. The Chinese government has poured over $20 billion into robotics and next-generation technologies, providing subsidies for startups and covering costs for equipment and talent acquisition. They're projected to match U.S. robotics research and development levels by 2034. Meanwhile, current U.S. tax code continues to disincentivize longer-term innovation projects by forcing companies to pay more up front for R&D. As the U.S. federal government increasingly overlaps its ambitions with AI tech companies, so too must it champion the development of humanoid robots as a national security and productivity imperative. How America Can Take The Lead Again In tandem with overcoming these inherent challenges, the U.S. must seize two unique opportunities that offer a high return on investment and a clear path to victory. Humanoid robots can maintain our edge in advanced manufacturing. Humanoids integrated with AI and embedded into the internet of things will create smart factories that enhance precision, improve product quality, and accelerate production times. The U.S. currently leads the world in the development of smart textiles —humanoid robots could accelerate production to maintain this advantage. Warehouses offer an arena for rapid humanoid adoption. The number of warehouses across the U.S. continues to expand, with Amazon recently announcing plans for dozens more across rural areas. Our vast network of warehouses is primed for humanoid robots to revolutionize its operations by automating sorting, packing, and transport alongside humans to boost efficiency and slash costs. These aren't theoretical applications: they're already being tested at sites like BMW's South Carolina plant, where robotics partners are deployed for logistics and warehousing tasks. These deployments leverage our existing strengths in technology and innovation while addressing real, immediate market needs. We don't need to wait for the perfect humanoid robot—we can start dominating these sectors today and build from there. This race not just about machines; it's about maintaining U.S. leadership in technology, safety, and industrial strength. If we want the next generation of robotics to serve American interests, we must act now or be left standing on the sidelines of the next industrial revolution. During my two decades at NASA, I saw what American innovators can achieve when given a mission. We sent robots to the Moon, Mars, and into orbit—not because it was easy, but because we believed it mattered for future generations. That same spirit must drive our investment in humanoid robotics today so we can cross the finish line first tomorrow.

Wall Street Journal
an hour ago
- Wall Street Journal
Podcast: Nike, Lululemon Shares Rise After Trump Touts Vietnam Trade Deal
Elsewhere in the markets, Centene shares tumble after the healthcare company says its earnings will fall short of expectations. Modelo brewer Constellation Brands expects President Trump's new tariffs to increase its costs by $20 million this fiscal year. 🎧 Listen: Ariana Aspuru hosts the WSJ's Minute Briefing podcast.
Yahoo
an hour ago
- Yahoo
Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company's disclosure of comprehensive MariTide tolerability data. 360b / The obesity medication's gastrointestinal tolerability profile unnerved the market, particularly the frequency of nausea and vomiting, which at first seemed more problematic than alternatives. Piper Sandler's study however, shows that both one- and two-step dose escalation regimens showed a noticeable improvement in the drug's tolerability profile, consistent with management's claims at the December top-line results announcement. According to the firm, the weight loss drug could produce a more commercially acceptable nausea and vomiting profile due to the much lower starting dosages and three-step dose escalation protocols included in the pivotal studies. Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤